Fenu, Elisabetta http://orcid.org/0000-0001-7666-3319
Lukyanov, Vasily
Acs, Annabel
Radu, Xenia
Stypa, Stephanie
Fischer, Aren
Marshall, John K.
Oppe, Mark
Funding for this research was provided by:
Takeda
Article History
Accepted: 10 March 2022
First Online: 26 April 2022
Declarations
:
: This work was supported by Takeda.
: Elisabetta Fenu is an employee of and holds stock or stock options in Takeda. Vasily Lukyanov and Xenia Radu are employees of IQVIA, which received funding from Takeda. Annabel Acs is a former employee of IQVIA, which received funding from Takeda. Stephanie Stypa and Aren Fischer are employees of Takeda Canada, Inc. John K. Marshall has received honoraria for speaking and/or consulting from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Lilly, Lupin, Merck, Novartis, Paladin, Pfizer, Pharmascience, Procter & Gamble, Roche, Shire, Takeda, and Teva. Mark Oppe is a former employee of Axentiva Solutions, which received funding from Takeda.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting the results reported in this article, will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Data are available upon request via application atExternalRef removed.
: Not applicable.
: Elisabetta Fenu, Aren Fischer, Vasily Lukyanov, Mark Oppe, Annabel Acs, and Xenia Radu were involved in the conception and design of the study. Elisabetta Fenu, Mark Oppe, and Aren Fischer analyzed and interpreted the data. All authors were involved in the acquisition of the data, drafted the article or critically revised it for intellectual content, and approved the final version for submission.